Panelists discuss the epidemiology, histologic diversity, and evolving biology of advanced renal cell carcinoma, setting the stage for modern treatment selection.
Back
Frontline Treatment Options in Advanced RCC
Panelists discuss the rapidly evolving frontline management of advanced renal cell carcinoma, highlighting progress in combination immunotherapy, precision-based treatment, toxicity management, and the promise of emerging therapies that are reshaping the standard of care.
Frontline Treatment Options in Advanced RCC
Episodes
All
All
Panelists review current guideline-endorsed first-line treatment options for advanced renal cell carcinoma, emphasizing immunotherapy- and VEGF inhibitor–based combination regimens.
Panelists analyze landmark clinical trial data supporting current frontline RCC therapies, focusing on response rates, progression-free survival, and overall benefit across risk groups.
Panelists discuss evolving evidence supporting adjuvant therapy in renal cell carcinoma and how these findings inform clinical decision-making.
Panelists discuss strategies for recognizing, preventing, and managing toxicities associated with frontline combination regimens in advanced renal cell carcinoma.
Panelists explore histology-specific and molecularly guided approaches that are expanding treatment options across renal cell carcinoma subtypes.
Panelists discuss emerging research directions and novel therapeutic combinations poised to shape the next generation of renal cell carcinoma management.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5